Apogee Therapeutics, Inc.

APGE

US03770N1019

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2024-07-15 EDT			5-day change	1st Jan Change
49.38 ^USD	+2.83%		+24.70%	+76.74%

07-01	Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from Russell Small Cap Comp Value Index	CI
07-01	Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from Russell 3000 Value Index	CI

Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from Russell 2500 Value Index

July 30, 2024

Latest news about Apogee Therapeutics, Inc.

Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from Russell Small Cap Comp Value Index	06-30	CI
Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from Russell 3000 Value Index	06-30	CI
Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from Russell 2500 Value Index	06-30	CI
Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from Russell 2000 Value Index	06-30	CI
Apogee Therapeutics, Inc.(NasdaqGM:APGE) dropped from Russell 3000E Value Index	06-30	CI
Apogee Therapeutics, Inc. Appoints Lisa Bollinger to Its Board of Directors	05-28	CI
Apogee Announces Dosing of First Patient in Phase 2 Atopic Dermatitis Trial of APG777, a Novel Subcutaneous Half-life Extended Anti-IL-13 Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases	05-15	CI
Apogee Therapeutics' Q1 Net Loss Widens	05-13	MT
Apogee Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-13	CI
BofA Securities Starts Coverage on Apogee Therapeutics With Buy Rating, $80 Price Target	05-10	MT
Apogee Therapeutics Announces First Participants Dosed in Phase 1 Trial of APG808, its Novel Half-life Extended IL-4Ra Antibody for the Treatment of Chronic Obstructive Pulmonary Disease and Other Inflammatory Diseases	03-25	CI
Apogee Therapeutics, Inc.(NasdaqGM:APGE) added to S&P Biotechnology Select Industry Index	03-17	CI
Apogee Closes $483 million Upsized Stock Offering	03-12	MT
Apogee Therapeutics Prices Upsized $420 Million Share Offering	03-08	MT
Sector Update: Health Care Stocks Advance Wednesday Afternoon	03-06	MT
Apogee Therapeutics Shares Rise After Jefferies Raises Price Target	03-06	MT
Jefferies Adjusts Price Target on Apogee Therapeutics to $75 From $37, Maintains Buy Rating	03-06	MT
Apogee Therapeutics Unveils $350 Million Share Offering	03-05	MT
Sector Update: Health Care Stocks Retreating Late Afternoon	03-05	MT
Sector Update: Health Care Stocks Lower Tuesday Afternoon	03-05	MT
Top Midday Gainers	03-05	MT
Sector Update: Health Care	03-05	MT
Apogee Therapeutics Shares Surge After Phase 1 Atopic Dermatitis Trial Data, Wedbush Price Target Raise	03-05	MT
Apogee Therapeutics Says Phase 1 Study of Atopic Dermatitis Drug Candidate Exceeds Objectives	03-05	MT
Wedbush Raises Apogee Therapeutics' PT to $87 From $40 After Reporting Initial Safety, PK Results From Phase 1 Trial of APG777; Maintains Outperform Rating	03-05	MT

Chart Apogee Therapeutics, Inc.

Duration

Period

More charts

Apogee Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma and other inflammatory and immunology (I&I) indications with high unmet need. Its advanced programs are APG777 and APG808, which are developed for the treatment of AD and COPD, respectively. APG777 is a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) targeting IL-13. APG808 is an SQ extended half-life mAb targeting IL-4RÎ±. Its earlier-stage programs, APG990 and APG222, utilize advanced antibody engineering to target OX40L and both IL-13 and OX40L, which are developed for the treatment of AD. APG990 is an SQ extended half-life mAb targeting OX40L for the treatment of AD. APG222 is one or more extended half-life SQ antibodies targeting both IL-13 and OX40L, which has the potential to improve outcomes in AD.

Sector

Biotechnology & Medical Research

Calendar

2024-08-25 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

49.38 USD

Average target price

84.83 USD

Spread / Average Target

+71.80%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
APOGEE THERAPEUTICS, INC.	+76.74%	2.89B
MODERNA, INC.	+22.15%	46.56B
LONZA GROUP AG	+45.43%	41.67B
IQVIA HOLDINGS INC.	-2.37%	41.16B
ALNYLAM PHARMACEUTICALS, INC.	+33.84%	32.4B
CELLTRION, INC.	-6.35%	28.1B
ICON PUBLIC LIMITED COMPANY	+20.42%	28.18B
UNITED THERAPEUTICS CORPORATION	+48.83%	14.52B
MEDPACE HOLDINGS, INC.	+45.00%	13.74B
BIO-TECHNE CORPORATION	+0.06%	12.17B

Other Biotechnology & Medical Research